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Abstract
Poly(lactic-co-glycolic acid) (PLGA) based microparticles (MPs) are widely investigated for their ability
to load a range of molecules with high efficiency, including antigenic proteins, and release them in a
controlled manner. Micron-sized PLGA MPs are readily phagocytosed by antigen presenting cells,
and localized to endosomes. Due to low pH and digestive enzymes, encapsulated protein cargo is
largely degraded and processed in endosomes for MHC-II loading and presentation to CD41 T cells,
with very little antigen delivered into the cytosol, limiting MHC-I antigenic loading and presentation
to CD81 T cells. In this work, PLGA was blended with poly(2-propylacrylic acid) (PPAA), a membrane
destabilizing polymer, in order to incorporate an endosomal escape strategy into PLGA MPs as an
easily fabricated platform with diverse loading capabilities, as a means to enable antigen presentation
to CD81 T cells. Ovalbumin (OVA)-loaded MPs were fabricated using a water-in-oil double emulsion
with a 0% (PLGA only), 3 and 10% PPAA composition. MPs were subsequently determined to have
an average diameter of 1 mm, with high loading and a release profile characteristic of PLGA. Bone
marrow derived dendritic cells (DCs) were then incubated with MPs in order to evaluate localization,
processing, and presentation of ovalbumin. Endosomal escape of OVA was observed only in DC
groups treated with PPAA/PLGA blends, which promoted high levels of activation of CD81 OVA-
specific OT-I T cells, compared to DCs treated with OVA-loaded PLGAMPs which were unable acti-
vate CD81 T cells. In contrast, DCs treated with OVA-loaded PLGA MPs promoted OVA-specific
OT-II CD41 T cell activation, whereas PPAA incorporation into the MP blend did not permit CD41
T cell activation. These studies demonstrate PLGA MP blends containing PPAA are able to provide
an endosomal escape strategy for encapsulated protein antigen, enabling the targeted delivery of
antigen for tunable presentation and activation of either CD41 or CD81 T cells.
K E YWORD S
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1 | INTRODUCTION
Biomaterials have traditionally been developed to avoid provoking
chronic aggravation of the immune system.1 This complex network of
cellular interactions and processes has evolved to provide protection
against foreign invaders as well as homeostatic regulation of self to
nonself. Strategies that aim to manipulate components of the immune
system, particularly polymer-based vaccines, have gained attention in
recent years.1–4 Polymeric microparticles (MPs) offer a distinct advant-
age as their intrinsic immunomodulatory properties and chemical versa-
tility fulfill desired properties in achieving long-term protection.
Generation of protective immunity following vaccination depends on
antigen availability, delivery to antigen presenting cells (APCs) and fur-
ther activation of innate immunity through the appropriate pathways.5
Current vaccination strategies are adept at generating antibodies and
CD41 T cell mediated immunity, but approaches to activate CD81 T
cell pathways, necessary to combat intracellular pathogens such as
malaria, HIV and cancer, are limited. Present strategies are based on
live-attenuated or inactivated pathogens that induce robust humoral
and cellular immunity. However, safety concerns associated with live
vectors limits their use in infants, the elderly and the immunocompro-
mised.6 Conversely, recombinant antigens based on peptides hold high
potential for CD81 T cell vaccine development but their dependency
on adjuvants remains a major hurdle to clinical translation.7 In this
study, we develop a unique polymer blend for the fabrication of micro-
particles that allow for the tuning of CD41 and CD81 T cell responses
through targeting of dendritic cells (DCs). We hypothesize incorpora-
tion of a small amount of Poly(2-propylacrylic acid) (PPAA) into a poly
(lactic-co-glycolic acid) (PLGA) matrix, will lead to endosomal escape
triggering cross-presentation pathway within DCs and further activa-
tion of CD81 T cells.
Dendritic cells are sentinels at the forefront of immunological
responses as the most efficient APCs and regulators of adaptive immu-
nity. Dendritic cells are constantly surveying the environment and are
able to uptake, process and present antigen to naïve T cells and appro-
priately shape the resulting T and B cell responses.8 T lymphocytes rec-
ognize peptide antigens presented by APCs in the context of the major
histocompatibility complex molecules (MHC) Class I and II. Peptides
derived from the cytosol are loaded onto MHC Class I in the lumen of
the endoplasmic reticulum and transported to the cell surface by
vesicles for recognition by CD81 T lymphocytes. Peptides generated
by the degradation of exogenous proteins in endosomes are bound to
MHC Class II and presented to CD41 T cells. Dendritic cells however,
have the ability to process exogenous proteins and present them in the
context of MHC Class I. This function, known as cross-presentation,
diversifies the ability of the immune system to generate immunity to
various pathogens.9
Microparticles fabricated of PLGA are one of the most widely used
biocompatible, biodegradable polymeric carriers with multiple applica-
tion in delivery of drugs, biomolecules and genes. PLGA systems are
able to efficiently load hydrophilic and hydrophobic molecules and can
easily be fabricated to specific micron size ranges, efficiently
phagocytosed by DCs, and allowing targeted delivery of antigen to
endosomal compartments. For sustained cytosolic delivery and activa-
tion of cross-presentation pathways an endosomal escape strategy
must be employed. Several compounds have been incorporated into
PLGA to allow blended formulation with improved stability, loading
and delivery capacity. Poly(2-propylacrylic acid), has the ability to rever-
sibly switch from a hydrophilic soluble conformation at physiological
pH to a hydrophobic and membrane interactive state in response to
acidic pH. Functionally, PPAA-containing systems trigger the disruption
of and release from acidified endosomal compartments, effectively tar-
geting cargo to cytosol. However, PPAA alone cannot readily support a
matrix capable of encapsulating bioactive molecules. Therefore, in this
study we incorporate PPAA into the PLGA matrix of MPs in order to
provide cytosolic delivery of a model antigen, while maintaining robust
properties of PLGA, thus accessing MHC-I loading and allowing the
tuning of CD41 and CD81 T cell responses.
2 | MATERIALS AND METHODS
2.1 | Materials
GMP grade PLGA (L/G550:50, Purasorb PDLG 5004A, intrinsic
viscosity50.4 dl/g) was purchased from Corbion Purac, Netherlands.
Poly(2-propylacrylic acid) (Mn520–80 kDa) and albumin from chicken
egg white (Ovalbumin, OVA, 98%, Grade V, molecular weight544,287
Da) was obtained from Sigma-Aldrich Co., St Louis, MO. Methylene
Chloride (MC) (99.9%), N,N-Dimethylformamide (DMF, 99.5%), bovine
serum albumin, and ethylenediamine tetraacetate acid were obtained
from Fisher Scientific, Fair Lawn, NJ. Polyvinyl alcohol (PVA, average
MW515,000 g/mol, 88.63% hydrolyzed) was supplied by MP Bio-
medicals LLC, Solon, OH. Mounting medium for fluorescence with
DAPI (sc-24941) was obtained from Santa Cruz Biotechnology Inc., CA.
4% paraformaldehyde solution in PBS (4% PFA) and 5-(and 6)-carboxy-
fluorescein diacetate N-succinimidyl ester (CFSE) were all obtained
from Affymetrix Inc, Cleveland, OH. Endotoxin levels were measured
using the ChromoLAL assay kit purchased from Associates of Cape
Cod, Inc., Falmouth, MA.
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12), fetal bovine serum (FBS), and Phosphate-buffered saline
(PBS) were purchased from GE Healthcare Life Sciences, Logan, UT.
L-glutamine, sodium pyruvate, nonessential amino acids (NEAA), and
ACK lysis buffer were obtained from Lonza, Walkersville, MD.
Penicillin-streptomycin solution (1003) was from Mediatech Inc, Man-
assas, VA. Granulocyte macrophage colony-stimulating factor (GM-
CSF) was supplied by R&D Systems, Minneapolis, MN. MACS LS col-
umns, mouse CD8a1 T cell isolation kit, and mouse CD41 T cell isola-
tion kit were obtained from Miltenyi Biotec, Auburn, Canada.
Molecular probes live/dead fixable Near-IR dead cell stain kit and DQ
ovalbumin were purchased from Life Technologies. Chicken egg albu-
min peptides OVA 257–264 and OVA 323–339 were supplied by
InvivoGen, San Diego, CA. BD Cytofix fixation buffer, purified rat anti-
mouse CD16/CD32 (mouse BD Fc block), APC antimouse CD4, and
APC rat antimouse CD8a were all from BD Biosciences, San Jose, CA.
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2.2 | Preparation of OVA-loaded PLGA-based
microparticles
OVA-encapsulated PLGA MPs were prepared using a modified double
emulsion water-oil-water (w/o/w) solvent extraction technique.10
Briefly, 100 mg of PLGA polymer was dissolved in methylene chloride
at 5% w/v ratio. 1 mg of OVA in PBS was added to 5% PLGA solution
and vigorously mixed for 120 s at 35,000 rpm using a homogenizer
(Fisher Scientific, NJ) to form a primary o/w emulsion. The emulsified
solution was then loaded into 4 ml of 5% (w/v) PVA in water and
homogenized for an additional 60 s at 35,000 rpm to form the second
emulsion. Finally, the w/o/w emulsion was poured slowly in 100 ml of
1% PVA in agitation to form microparticles. The solution remained in
agitation with a magnetic stirrer overnight at room temperature to
evaporate methylene chloride and stabilize microparticles. The remain-
ing solution was centrifuged at 10,000 rpm for 15 min to collect fabri-
cated MPs and subsequently rinsed three times with PBS to remove
uncaptured OVA. Collected MPs were lyophilized in a freeze-dryer for
2 days and stored at 2208C for later use.
PPAA/PLGA blend MPs were fabricated with a modified protocol.
PPAA (100 mg) were dissolved in 2 ml of DMF while 90 mg of PLGA
were dissolved in 1.8 ml of MC for 10% PPAA/PLGA blend or 97 mg
in 1.94 ml for 3% PPAA/PLGA blend. After polymer dissolution, 10 mg
of PPAA (200 ll of PPAA solution in DMF) was added to 90 mg of
PLGA in MC solution or 3 mg of PPAA (60 ll of PPAA solution in
DMF) was added to 97 mg of PLGA in MC solution. In other words,
100 mg of PLGA-PPAA (w/w) blend polymer was dissolved in a total
of 2 ml of organic solvent methylene chloride/DMF. One milligram of
OVA in PBS was added to 5% PLGA-PPAA blend solution and vigo-
rously mixed for 105 s (for 3% PPAA) or 75 s (for 10% PPAA) at
35,000 rpm to form a primary emulsion. The emulsified solution was
loaded into 4 ml of 5% (w/v) PVA, pH 6.0 and re-emulsified for addi-
tional 45 s (for 3% PPAA) or 15 s (for 10% PPAA) at 35,000 rpm. The
second emulsion was poured slowly in 100 ml of 1% PVA, pH 6.0 in
agitation to form microparticles.
Prior to fabrication, glassware used during process was heated to
2508C for 4 hr to minimize endotoxin contamination. Homogenizer
was sterilized by submerging components in ethanol overnight and all
solutions filtered sterilized. Microparticles were then tested for endo-
toxin content using the ChromoLAL method in accordance with manu-
facturer’s instructions.
2.3 | Characterization of OVA-loaded PLGA-based
microparticles
The size and zeta potential of the different OVA-encapsulated PLGA-
based MPs were determined using a Microtrac Nanotrac Dynamic
Light Scattering Particle Analyzer (Microtrac, Montgomery, PA) and a
Brookhaven ZetaPlus zeta potential analyzer (Brookhaven Instruments
Corp., NY), respectively. Scanning electron microscopy (FEG-SEM
JEOL JSM—6335F, Major Analytical Instrumentation Center, University
of Florida) was used to confirm size distribution and morphology of
MPs. Lyophilized microparticles were suspended in DI water and
deposited on glass coverslips over a double sided conductive tape
attached to a metal stub. Samples were dehydrated overnight in a des-
iccator followed by sputter-coating with gold/palladium before image
collection at 10–15 kV.
To determine the loading efficiency of PLGA-based MPs, 10 mg of
microparticles were dissolved in 200 ll of MC followed by the addition
of 1% tween 20 in PBS to disperse the protein into the aqueous phase.
The suspension was centrifuged and the supernatant moved to a new
tube. 200 ml of methylene chloride was added to the pellet to dissolve
any remaining polymer and further encapsulated release protein. This
process was repeated three times. The OVA concentration of the
extracted aqueous solution was determined using a Nanodrop spectro-
photometer ND1000 (ThermoScientific, Wilmington, Delaware), com-
pared with a standard calibration curve of data obtained by series of
known concentrations of OVA solution.
To evaluate the release profile of OVA from PLGA-based MPs,
1 mg of MPs was suspended in 1 ml of PBS. Tubes were kept under
agitation at 200 rpm at 378C. At predetermined time points, MPs were
centrifuged at 10,000 rpm for 10 min and 200 ll of the supernatant
collected and stored at 2208C until further analysis. The medium col-
lected was replenished with fresh PBS and particles were vortexed and
placed back in the incubator. The concentration of OVA released from
MPs was measured by micro BCA protein assay kit (ThermoScientific,
Rockford, IL), according to manufacturer’s instructions.
2.4 | Mice
The studies reported here conform to the animal welfare ACT and the
National Institutes of Health guidelines for the care and use of animals
in the biomedical research. All experiments were completed in compli-
ance with the regulations of the University of Florida Institutional Ani-
mal Care and Use Committee and in accordance with the guidelines of
the Association for Assessment and Accreditation of Laboratory Animal
Care. Eight to 12-week old C57BL/6J (wild type, WT) transgenic OT-I
and OT-II on a C57BL/6J background were purchased from the
Jackson Laboratory.
2.5 | Isolation and culture of murine bone marrow
dendritic cells
Dendritic cells were derived from mouse bone marrow as previously
described.11 In brief, mice were euthanized by CO2 asphyxiation fol-
lowed by cervical dislocation. Tibias and femurs were harvested and
marrow cells collected by flushing the shafts of the bones with a 25-g
needle using wash media (RPMI medium containing 10% heat inacti-
vated filter sterilized fetal bovine serum, and 1% penicillin–streptomy-
cin) and mixed to obtain a single-cell suspension. The solution was
then strained through a 70 mm cell strainer and centrifuged at
1,700 rpm for 5 min at 48C. Erythrocytes were then removed by resus-
pending in ACK lysis buffer for 5 min at room temperature and centri-
fuging at the conditions specified above. Resulting cells were cultured
in DC media (complete DMEM/F12 medium containing 2.5 mM L-glu-
tamine, 100 U/ml penicillin–streptomycin, 10% heat inactivated filter
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sterilized FBS, 1 mM sodium pyruvate, and 1x NEAA mixture and 20
ng/ml GM-CSF). Monocytes were selected by plastic adherence for 6
days at 378C with 95% relative humidity and 5% CO2. The culture was
fed every 2 days by gently aspirating 50% medium and adding fresh
medium. On day 6 of culture, the medium was discarded and non/
loosely adherent cells containing dendritic cells were collected. A
single-cell suspension of cells was then plated immediately in round
coverslips placed in 6-well plates at 5 x 105 cells/well for endosomal
disruption study, or in round-bottom 96-well micro-titer plates (Corn-
ing, Corning, NY) at 2.5 x 104 cells/well for T cell proliferation assay.
2.6 | Endosomal disruption by PPAA/PLGA
microparticles
After overnight incubation with 100 lg of DQ-OVA according to pub-
lished methods,12 different PLGA-based microparticles were washed
with PBS three times to remove unbound dye and then loaded to rele-
vant experimental groups of cultured DCs at a 3:1 ratio (MPs: cells) in
DC media for 1 hr at 378C on day 8 of DC culture. To determine the
number of MPs, 0.5 mg were dissolved in 10 ml of water and counted
using a hemocytometer. The cells were then washed three times with
warm PBS to remove MPs that were not phagocytosed and cultured in
complete DMEM/F12 medium containing GM-CSF for 3 days. Each
day, DCs were fixed with 4% PFA for 10 min at room temperature.
Cell nuclei were stained with Hoechst 33342. Coverslips were then
mounted on microscope slides and phase contrast microscopy of cells
was performed on a Zeiss Axiovert 200 M using 40X objective lens
(Carl Zeiss Microscopy, Thornwood, NY). FITC/DC area was calculated
by measuring the fluorescence intensity for each channel and calcu-
lated using the AutoMeasure module within AxioVision Rel. 4.8. Briefly,
parameters (intensity, brightness, area of interest) were determined
using image segmentation. Then, artifacts are removed and object sep-
aration performed to determine the number of regions to be analyzed
within each channel. Then, the area sum, in um2, of the outlined
regions was determined. The area sum of the FITC channel was then
divided by the area sum of the DAPI channel.
2.7 | T cell proliferation assay by flow cytometry
On day 8 of culture, DCs were seeded with OVA-loaded PLGA-based
microparticles at a 50:1 ratio (MPs: cells) and incubated for an addi-
tional 2 days. On day 10, CD41 and CD81 T cells were isolated from
the spleen of OT-I and OT-II 8-week old female mice. Briefly, animals
were euthanized by CO2 asphyxiation followed by cervical dislocation.
Spleens were aseptically harvested and homogenized in wash media.
Cells were then passed through a 70 mm cell strainer and centrifuged
at 1,700 rpm for 5 min at 48C. Red blood cells were eliminated using
ACK lysis buffer followed by centrifugation to recover lymphocytes.
CD41 and CD81 T cells were purified using a negative selection isola-
tion kit according to manufacturer’s instructions. Resulting cells were
stained with 5 mM CFSE for 10 min at room temperature to track pro-
liferation. DCs were washed of particles three times with warm PBS
and relevant groups pulsed with 100 ll of 2 lg/ml OVA peptides,
323–339 or 257–264, in DC media for 3 hr. DCs and T cells were co-
cultured for 4 days at a 1:10 ratio with a half media change on day 2.
On the specified days, T cells were collected by centrifugation, washed
with PBS containing 1% FBS, stained with live/dead NIR dye, and anti-
bodies against surface markers CD4 or CD8 for 30 min at 48C and
fixed with BD Cytofix fixation buffer for 20 min at 48C. Proliferation
was measured by CFSE dilution using a Guava EasyCyte (EMD Milli-
pore) flow cytometer. Data analysis was performed using FCS Express
version 3 (De Novo Software, Los Angeles, CA).
2.8 | Statistical analysis
Data reported were analyzed and charts were generated using Prism
5.0 (GraphPad, San Diego, CA). Statistics were done using a one-way
ANOVA followed by Tukey’s post hoc analysis to make pair-wise com-
parisons, with 95% confidence intervals. Two-way ANOVA was used
to determine differences in T cell proliferation with a Bonferroni’s post
hoc analysis. Unless otherwise indicated, data represent the mean6
SEM, with p< .05 considered statistically significant.
3 | RESULTS
3.1 | Microparticle characterization
Polymer blend MPs with fabrication compositions of 0% PPAA (PLGA
only), 3% PPAA/PLGA and 10% PPAA/PLGA were loaded with ovalbu-
min by double emulsion solvent evaporation. Endotoxin level was
tested by the ChromoLAL method against a standard curve and deter-
mined to be 0.47, 0.23, and 0.37 EU/mg for the PLGA only, 3% PPAA/
PLGA, and 10% PPAA/PLGA MPs, respectively. Values are well below
acceptable endotoxin levels for vaccine formulations in preclinical mod-
els.13 Microparticles were characterized by determining their size distri-
bution and morphology, zeta potential, surface pH, loading and in vitro
release kinetics. The size range of MPs was determined by dynamic
light scattering, calculated by volume to be 160.4 mm for the PLGA
only, 1.160.3 mm for the 3% blend, and 160.4 mm for the 10% blend
with a polydispersity index of 0.23, 0.21, and 0.10, respectively (Figure
1a–c). Scanning electron microscopy images confirmed size distribution
of 1 mm in diameter as well as a spherical shape and smooth surfaces
for all three microparticle formulations (Figure 1d–f). Zeta potential
analysis revealed MPs are negatively charged under aqueous condi-
tions with specific values of 22160.4 mV for PLGA only, 222.560.6
mV for 3% PPAA blend, and 223.460.6 mV for the 10% PPAA blend
(Figure 1g). The negative surface charge increased modestly, in propor-
tion to the percentage of PPAA in the formulation of PPAA/PLGA
blend microparticles, which suggested that PPAA was partly present on
the surface and increasing negativity was due to deprotonated carboxyl
of PPAA. All formulations showed effective loading, with PLGA only
MPs encapsulating 1.760.03 lg OVA/mg MP, 3% PPAA/PLGA MPs
1.960.02 lg/mg MP, and 10% PPAA/PLGA MPs 2.0060.02 lg/mg
MP, respectively (Figure 2).
The in vitro release kinetics from the three microparticle formula-
tions was examined in PBS for 30 days. Briefly, particles were
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suspended in PBS and incubated at 378C under constant agitation.
Samples were centrifuged and supernatant collected daily. A burst
release was observed during the initial phase with a cumulative per-
centage of 14.860.3% for the PLGA only, 17.460.8% for the 3%
PPAA/PLGA blend, and 21.061.2% for the 10% PPAA/PLGA blend.
On completion of the 30-day incubation, total cumulative ovalbumin
released from MPs was 62.462.1% for PLGA, 81.962.4% for 3%
PPAA/PLGA blend, and 91.261.8% for 10% PPAA/PLGA blend. How-
ever, the complete release of the theoretical maximum encapsulated
OVA in the three types of MPs was not achieved over the course of
the study (Figure 3).
3.2 | PPAA-mediated endosomal disruption
The PPAA-mediated endosomal escape was examined by micros-
copy using DQ-OVA, a fluorogenic protease substrate. A strong flu-
orescence quenching effect is observed when proteins are heavily
labeled with BODIPY dyes. On hydrolysis of DQ-OVA to single,
dye-labeled peptides by proteases, quenching is relieved, producing
brightly fluorescent products. After incubation with DCs for 3 days,
DQ-OVA labeled particles became detectable in the cytosol, deter-
mined by diffused fluorescence, versus endosomes, established by
punctate florescence patterns14 (Figure 4a). The intensity of cyto-
solic localization markedly increased for all three microparticle
(a) (b) (c)
(d)
(g) (h)
(e) (f)
FIGURE 1 PLGA and PPAA/PLGA blend MPs characterization. Size distribution of (a) PLGA MPs, (b) 3% PPAA/PLGA MPs, (c) 10% PPAA/
PLGA MPs, as determined by dynamic light scattering. Morphology of (d) PLGA MPs, (e) 3% PPAA/PLGA MPs, and (f) 10% PPAA/PLGA
MPs visualized through scanning electron microscopy. Scale bar represents 10 lm (d, e) and 5 lm (f). (g) Zeta potential and (h) pH of PLGA
and PPAA blend MPs were measured. The data shown represent mean6 standard error of the mean (SEM). Values of p (where *<.05 and
***<.001) were calculated using a nonparametric one-way ANOVA with a Tukey’s post-test
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formulations over the course of the study (Figure 4b). Interestingly,
the 10% PPAA/PLGA blend MPs showed promoted cytosolic local-
ization in the first day with 7.962.5% FITC area/DC area, com-
pared to 3.262.4%, and 0.660.2% for the 3% blend and the PLGA
only formulations, respectively. Although PLGA only MPs were also
able to escape the endosome to some degree, a significant increase
was observed with both the 3 and 10% blend. The capacity to dis-
rupt endosomal membranes increased directly proportional to the
percentage of PPAA in the particle formulation.
3.3 | Antigen-specific T cell proliferation study
DCs pretreated for 24 hr with OVA-loaded microparticle formula-
tions were co-cultured with CFSE-labeled OVA-specific T cells for 5
days. As shown in Figure 5a,b, DCs incubated with PLGA only MPs
triggered significantly higher CD41 T cell proliferation beginning on
day 4 compared to 3% PPAA/PLGA blend and 10% PPAA/PLGA
blend. However, neither of the two PPAA blends promoted CD41 T
cell proliferation during the 5-day study. These results demonstrate
PLGA MPs primarily target delivery to endosomes and promote
MHC Class II presentation. In contrast, DCs treated with 3% PPAA/
PLGA blend MPs and 10% PPAA/PLGA blend MPs triggered signifi-
cantly elevated CD81 T cell proliferation compared to PLGA MPs,
beginning on the day 3 (Figure 5c,d), whereas thePLGA MP was no
different from the negative controls. These results demonstrate
OVA encapsulated in PPAA/PLGA MPs is effectively delivered to
the cytosol, enabling loading, and presentation on MHC-I to activate
CD81 T cells.
4 | DISCUSSION
This study has provided a novel approach to endosomal escape strat-
egies, enabling the tuning of antigen delivery to either endosomal or
cytosolic compartments to shape subsequent CD41 and CD81 T cell
responses. Particles of approximately 1 mm in size were fabricated
using PPAA/PLGA polymer blends, and were effectively phagocytosed
by murine bone marrow derived DCs. The PPAA component allowed
for disruption of endosomes, leading to the release of cargo into the
cytosol and presentation of antigen on MHC Class I molecules. MHC-I
presentation by DCs was confirmed by the activation of CD81 T cells
in a manner directly proportional to the amount of PPAA present in
the blend.
Enhancing endosomal escape of endocytosed therapeutic pro-
tein antigens can increase the efficacy of protein vaccines through
increased activation of cytotoxic T lymphocytes. These CD81 T
cells are capable of specifically recognizing malignant cells or cells
infected with pathogens, leading to the activation and proliferation
of effector cells which then exert cytotoxic functions to eliminate
compromised cells. As such, various mechanism for endosomal
membrane disruption have been proposed in the last decade,
including strategies utilizing ultrasound,15–17 enzymatic
degradation,18–20 pH,21,22 and light.23 In addition to these efforts,
biodegradable polymeric delivery systems have attracted significant
attention due to their loading capability, low toxicity, and ease of
use. A number of studies have shown that particle size, particle
charge, and delivery site have an impact on uptake and immune
stimulation.24–27 Nanometer-scale particles can be taken up
through pinocytosis, a mechanism not exclusive to APCs, whereas
particles larger than 7 mm are not efficiently engulfed, and the
cargo released in the extracellular space.28 These studies, in combi-
nation with previous work in our lab,10,29–32 guided the design cri-
teria of the microparticle formulations. The polymer blends
investigated herein consisted of PPAA, a pH responsive anionic
polymer, and PLGA, a well characterized polymer. Microparticles
were fabricated using a modified double emulsion water-oil-water
FIGURE 2 Encapsulation efficiency of PLGA and PPAA/PLGA
blend MPs. Mass of ovalbumin encapsulated in each MP
formulation. Data are shown as mean6 SEM for n53 for each
microparticle formulation. Values of p (where ***<.001) were
calculated using a nonparametric one-way ANOVA with a Tukey’s
post-test
FIGURE 3 In vitro release profiles of ovalbumin from MPs. In
vitro cumulative release profile of OVA from PLGA (·), 3%PPAA/
PLGA (), and 10%PPAA/PLGA () MPs during 30-day incubation
at 378C in PBS buffer (pH 7.4). Data are presented as a percentage
of the total amount of OVA initially encapsulated in t micropar-
ticles. Shown are mean6 SEM based on n53 for each MP
formulation
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(w/o/w) solvent extraction method. PLGA not only acted as a
hydrophobic core that facilitated the formation of the blend par-
ticles, but also minimized degradation by serving as the structural
support for the encapsulation of antigen. Fabricated MPs incorpo-
rating PPAA maintained similar size and morphology, with only
small shifts in surface charge, and loading amounts.
Application of biodegradable MPs as an antigen delivery system
depends on the ability to release payload in a controlled fashion. All
three formulations demonstrated an initial burst followed by a steady
release phase of encapsulated antigen. The 10% PPAA/PLGA blend
MPs demonstrated a modestly faster and higher cumulative release,
where the rate of release was directly proportional to the PPAA con-
tent. Previous work by Acu~na et al. demonstrated electrostatic repul-
sion between oxygen atoms in ether groups of poly(ethylene oxide)
and bovine serum albumin33 a weak polyelectrolyte and modestly neg-
atively charged protein. Work by Weijers et al. demonstrating a stron-
ger negative charge of OVA34 plus the increased polarity of carboxyl
groups, compared to ether, lead us to believe a strong repulsion
between the two is possible. Although not tested here, we hypothesize
the negatively charged carboxyl groups on PPAA lead to a charge
repulsion-based faster release of the negatively charged encapsulated
OVA protein.
FIGURE 4 MP-mediated endosomal disruption. Endosomal disruption was analyzed by microscopy. (a) Representative microscope images
of DCs with DQ-OVA adsorbed MPs, PLGA (left), 3%PPAA/PLGA blend (middle), and 10%PPAA/PLGA blend (right) from day 2 of 3 day
test period. Top, blue stained cell nuclei. Middle, green labeled DQ-OVA MPs. Bottom, merged images of cell nuclei, and DQ-OVA MPs.
Scale bar, 20 lm. (b) Microscopy-based quantification of microparticles escaped from endosome to cytosol of DCs. Data are presented as
mean6 SEM for n 53. Values of p (where *<.05 and ***<.001) were calculated using a two-way ANOVA with a Bonferroni post-test
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The ability of PPAA to promote endosomal escape of loaded anti-
gen was examined using murine bone marrow derived DCs. Dendritic
cells incubated with PLGA MPs showed a punctuate pattern of fluores-
cence indicating localization within endosomal compartments. In con-
trast, the extent of cytosolic distribution dramatically increased in cells
incubated with PPAA/PLGA MPs. While the precise mode of endoso-
mal escape was not addressed here, previous work has demonstrated
the protonation of PPAA carboxylate ions into deionized carboxylic
acid groups at lower pH values encountered during endosomal traffick-
ing causes PPAA to partition into membranes, disrupting the lamellar
structure, and releasing internalized material.35–40 Lastly, DCs treated
with all three microparticle formulations were co-cultured with
antigen-specific T cells to assess activation of MHC-I versus MHC-II
loading, and stimulation of the cognate T cell subset. Results demon-
strate PLGA MPs are promote delivery of antigen to endosomal com-
partments activating CD41 T cells. Notably, MPs containing PPAA
(a) (b)
(c) (d)
FIGURE 5 Flow cytometric analysis of OVA specific carboxyfluorescein succinimidyl ester (CFSE) stained T-cell proliferation assay stimu-
lated MPs-treated BMDCs. (a) Murine bone marrow derived DCs were incubated with PPAA/PLGA MPs, PLGA MPs for 24 hr or pulsed
with OVA peptide 323–339 for 3 hr as a positive control. DCs where then washed and co-cultured with CD41 CFSE labeled T cells iso-
lated from OT-II mice for 5 days. Each day cells were pulled, live/dead, and CD4 stained and proliferation assessed via CFSE dilution by
flow cytometry. (b) Representative flow gating scheme of negative (top) and positive (bottom) controls shown. (c) DCs were incubated with
polymer blend and PLGA only MPs for 24 hr or pulsed with OVA peptide 257–264 for 3 hr as a positive control. DCs were washed and
co-cultured with CD81 T CFSE labeled T cells isolated from OT-I mice for 5 days. Cells were pulled every day, live/dead, and CD8 stained
and proliferation addressed through CFSE dilution by flow cytometry. (d) Representative flow cytometry gating scheme for negative (top)
and positive (bottom) controls
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efficiently promoted delivery of antigen to the cytosol, loading onto
MHC Class I molecules and presentation to CD81 T cells, at levels
comparable to the positive control.
5 | CONCLUSIONS
Particulate vaccine carriers have been extensively reported in recent
years. Despite decades of research, endosomal escape for cytosolic
delivery of antigen in APCs for subsequent activation of cytotoxic T
cells is still considered a bottleneck in the design of efficacious vac-
cines. This study utilized a biodegradable polymeric blend carrier com-
posed of PLGA and PPAA, a pH sensitive membrane destabilizing
polymer, to induce endosomal escape and target cytosolic delivery of
antigen. We demonstrated microparticles fabricated of PPAA/PLGA
blends maintained high encapsulated amounts of OVA and showed
similar release kinetics to MPs fabricated of PLGA only. In addition,
PPAA/PLGA blend MPs were able to target cytosolic delivery of cargo,
whereas PLGA MPs remained primarily in the endosome. This was
demonstrated through co-cultures of DCs treated with MPs with
OVA-specific transgenic T cells. CD41 T cells only proliferated when
activated by DCs treated with OVA-loaded PLGA microparticles,
whereas CD81 T cells became activated only in response to DCs
treated with OVA-loaded PPAA/PLGA microparticle blends. This work
indicates that blends of PPAA incorporated into PLGA as a controlled
release delivery system maintain the ease of fabrication and loading
versatility of PLGA, while enabling tunable CD41 and CD81 T cell
responses to improve design of new vaccines.
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